Brady James Aloysius

SEC Form 4 insider trading activity

Brady James Aloysius has filed 3 SEC Form 4 filings (5 transaction rows) across 2 companies, including XERS, VRNA, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jun 5, 2026.

On the most recent filing, Brady James Aloysius is listed as Director at Xeris Biopharma Holdings, Inc. Inside the rolling window, Brady James Aloysius reported no open-market purchases and 1 open-market sale totaling $60K in XERS.

Companies traded

Other insiders at XERS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$60K

reported sales (SEC code S)

Companies

2

in the rolling window

Source
XERS
Brady James Aloysius
Sale$60KApr 1SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Brady James Aloysius made?

Brady James Aloysius has filed 3 SEC Form 4 filings (5 transaction rows) across 2 companies, including XERS, VRNA since 2025.

Which companies does Brady James Aloysius trade?

Brady James Aloysius has filed SEC Form 4 disclosures for 2 companies, including XERS, VRNA.

When was Brady James Aloysius's most recent SEC Form 4 filing?

Brady James Aloysius's most recent SEC Form 4 filing on Tracefour is dated Jun 5, 2026.

What is Brady James Aloysius's total buy and sell value in the current window?

Inside the rolling retention window, Brady James Aloysius bought $0 and sold $60K based on SEC Form 4 filings.

What was Brady James Aloysius's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 10,834 XERS shares on 2026-03-30, worth $60K, per SEC Form 4 filings.